Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$96.28
+1.4%
$93.24
$52.50
$99.50
$2.09B0.58361,253 shs66,300 shs
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$2.32
+10.8%
$2.58
$0.66
$3.60
$524.11M1.942.42 million shs4.34 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$33.78
+6.1%
$28.31
$24.07
$55.33
$2.05B2.381.30 million shs452,364 shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$29.46
+4.5%
$26.17
$18.53
$51.61
$1.87B1.231.36 million shs326,034 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
+1.22%+3.21%-0.45%+40.63%+60.74%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-5.43%-9.52%-32.14%+13.59%+135.10%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+2.48%+3.51%+15.16%-11.56%-22.54%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-5.81%-7.57%+8.63%+29.30%-29.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$96.28
+1.4%
$93.24
$52.50
$99.50
$2.09B0.58361,253 shs66,300 shs
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$2.32
+10.8%
$2.58
$0.66
$3.60
$524.11M1.942.42 million shs4.34 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$33.78
+6.1%
$28.31
$24.07
$55.33
$2.05B2.381.30 million shs452,364 shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$29.46
+4.5%
$26.17
$18.53
$51.61
$1.87B1.231.36 million shs326,034 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
+1.22%+3.21%-0.45%+40.63%+60.74%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-5.43%-9.52%-32.14%+13.59%+135.10%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+2.48%+3.51%+15.16%-11.56%-22.54%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-5.81%-7.57%+8.63%+29.30%-29.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
2.90
Moderate Buy$99.144.47% Upside
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
2.67
Moderate Buy$8.50306.70% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.64
Moderate Buy$48.5652.55% Upside
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
2.64
Moderate Buy$61.50118.09% Upside

Current Analyst Ratings Breakdown

Latest GOSS, ANIP, TWST, and VERA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/16/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$48.00
10/9/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$77.00 ➝ $90.00
10/8/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-)Sell (D+)
10/8/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/7/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$46.00 ➝ $42.00
10/2/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$45.00 ➝ $40.00
9/27/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
9/27/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$747.40M2.76$7.69 per share12.34$19.11 per share4.97
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$114.70M4.14N/AN/A$0.13 per share16.08
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.14N/AN/A$8.07 per share3.94
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/A$9.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$0.77N/A22.54N/A-1.37%25.03%8.00%11/14/2025 (Estimated)
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%11/6/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%11/17/2025 (Estimated)
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$152.15M-$3.58N/AN/AN/AN/A-46.70%-39.46%11/6/2025 (Estimated)

Latest GOSS, ANIP, TWST, and VERA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/17/2025Q4 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.40N/AN/AN/A$97.40 millionN/A
11/14/2025Q3 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.74N/AN/AN/AN/AN/A
11/6/2025Q3 2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.19N/AN/AN/A$6.32 millionN/A
11/6/2025Q3 2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$1.20N/AN/AN/AN/AN/A
9/8/2025Q2 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/A$1.80N/AN/AN/A$211.37 million
8/8/2025Q2 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.42$1.80+$0.38$0.36$187.18 million$211.37 million
8/5/2025Q2 2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 million
8/5/2025Q2 2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$0.82-$1.20-$0.38-$1.20N/AN/A
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.39
2.54
1.96
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/A
4.40
4.40
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.16
17.03
17.03

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
81.23%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
99.21%

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
11.10%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
16.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.70 million19.29 millionOptionable
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
180227.38 million212.15 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
4063.82 million53.42 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$96.28 +1.38 (+1.45%)
As of 11:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Gossamer Bio stock logo

Gossamer Bio NASDAQ:GOSS

$2.32 +0.23 (+10.77%)
As of 11:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$33.78 +1.95 (+6.11%)
As of 11:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Vera Therapeutics stock logo

Vera Therapeutics NASDAQ:VERA

$29.46 +1.26 (+4.45%)
As of 11:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.